Clinical Trials
39 trialsTroFuse-031
Merck Sharp & Dohme LLC
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
ADAPT-BLADDER
Hoosier Cancer Research Network
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
University of Florida
Intravesical Gem/Doce in Patients With NMIBC
University of Arizona
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
KEYVIBE-005
Merck Sharp & Dohme LLC
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
GAIN INST
Hospital Centre Biel/Bienne
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Zhuhai Beihai Biotech Co., Ltd
Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients
Dokuz Eylul University
POLO
University of Bern
RANGE
Eli Lilly and Company
Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma
NanOlogy, LLC
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Canadian Cancer Trials Group
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
Eastern Cooperative Oncology Group
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
University of California, Davis
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Hoosier Cancer Research Network
MK-3475-045
Merck Sharp & Dohme LLC
FIERCE-21
Rainier Therapeutics
A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]
Hoffmann-La Roche
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Dana-Farber Cancer Institute
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
University of Michigan Rogel Cancer Center
Docetaxel in Treating Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Salvage Docetaxel for Pretreated Urothelial Cancer
Samsung Medical Center
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
University of Colorado, Denver
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer
University of Chicago
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Chemotherapy in Treating Patients With Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
Stanford University
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center